secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2021-08-06T23:59:59+00:00
Accession:  0001104659-21-101093
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience Q3 revenue $35M (+65% YoY); raises FY2021 guidance
-------------------------------------------------------------------

- Revenue $35.0M vs $21.2M YoY; orders $39.1M (+58% YoY).
- Net loss $40.0M ($0.82/share) vs $28.2M ($0.67) YoY.
- Gross margin 40%; cash $519.4M; raising FY2021 revenue guidance.
- Shipped 107,000 genes (vs 83,000 YoY); acquired iGenomX for NGS tools.
- Began shipping synthetic SARS-CoV-2 Delta RNA controls; appointed Dr. Melissa Starovasnik to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/0001104659-21-101093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000110465921101093/tm2123937d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-101093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer